Immune system stimulation via exposure to attenuated poliovirus antigens

Exposure to attenuated poliovirus antigens, typically via oral poliovirus vaccine (OPV), stimulates broad immune responses comprising both mucosal (IgA-mediated) and systemic (serum IgG-mediated) protection through the activation of CD4+ and CD8+ T cells and the production of virus-neutralizing antibodies[1][4][7]. Attenuated poliovirus engages antigen-presenting cells—including dendritic cells and macrophages—leading to robust priming of both Th1 and cytotoxic T cell immunity, as well as the promotion of B cells for antibody generation[1][2][5]. This process underlies protective immunity against poliovirus infection and represents a basis for recombinant vaccine platforms and experimental cancer immunotherapy[5][6]. However, this is not a single molecular target or classical receptor/protein but rather describes an immunological outcome or intervention pathway.

Other names

Immune stimulation with attenuated poliovirusImmune response to attenuated poliovirus antigensMucosal immunity induced by live-attenuated poliovirus vaccine

Antigen presentation by antigen-presenting cells (APCs) leading to activation of T cells (CD4+, CD8+) and B cell help[1][2][5]; Induction of mucosal IgA and serum neutralizing antibodies through vaccination[4][7]; Priming of cytotoxic T cell responses by delivery of antigen using attenuated/recombinant poliovirus[2][5][6]